Bristol-Myers beats profit estimates, thanks to strong Yervoy, Eliquis numbers

Bristol-Myers Squibb's ($BMY) melanoma drug Yervoy and clot-fighter Eliquis helped boost its earnings past analyst forecasts, with $333 million in profits on $3.9 billion in revenue. Compared with the same period last year, that's a decline in sales, but that's because Bristol-Myers sold out of its diabetes partnership with AstraZeneca ($AZN) later in the year. Report

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…